Intratumoral Injection of Autologous CD1c (BDCA-1)+ myDC, AS01B, and Ipilimumab Plus Systemic Nivolumab (clinicaltrials.gov) - Sep 29, 2026 - P1/2 | N=18 | Active, not recruiting | Sponsor: Universitair Ziekenhuis Brussel | Trial primary completion date: Dec 2025 ➔ Apr 2027 | Recruiting ➔ Active, not recruiting | Trial completion date: Dec 2025 ➔ Dec 2027
Enrollment closed • Trial completion date • Trial primary completion date • Oncology • Solid Tumor
|